Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Simons

Showing results (801-810 of 814) with videos related to

Pageof 82
Sort By:
The Journal of Allergy and Clinical Immunology|September 14, 2020
ARGX-117, a therapeutic complement inhibiting antibody targeting C2Inge Van de Walle, Karen Silence, Kevin Budding, et al.
Physical Review Letters|March 2, 2019
Experimental Evidence for Transverse Wobbling in ^{105}PdJ Timár, Q B Chen, B Kruzsicz, et al.
Parkinsonism & Related Disorders|June 2, 2009
GIGYF2 mutations are not a frequent cause of familial Parkinson's diseaseAlessio Di Fonzo, Edito Fabrizio, Astrid Thomas, et al.
Human Gene Therapy|August 20, 1996
Human gene marker/therapy clinical protocolsS A Rosenberg, R M Blaese, M K Brenner, et al.
Journal of Medical Genetics|November 8, 2005
The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestorS Goldwurm, A Di Fonzo, E J Simons, et al.
Human Gene Therapy|December 28, 1999
Human gene marker/therapy clinical protocolsS A Rosenberg, R M Blaese, M K Brenner, et al.
Human Gene Therapy|December 1, 1996
Human gene marker/therapy clinical protocolsS A Rosenberg, R M Blaese, M K Brenner, et al.
Human Gene Therapy|February 4, 1998
Human gene marker/therapy clinical protocolsS A Rosenberg, R M Blaese, M K Brenner, et al.
European Journal of Human Genetics : EJHG|December 8, 2005
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's diseaseAlessio Di Fonzo, Cristina Tassorelli, Michele De Mari, et al.
Royal Society Open Science|July 25, 2024
Subjective evidence evaluation survey for many-analysts studiesAlexandra Sarafoglou, Suzanne Hoogeveen, Don van den Bergh, et al.
Pageof 82

Showing results (801-810 of 814) with videos related to

Sort By:
Pageof 82
The Journal of Allergy and Clinical Immunology|September 14, 2020
ARGX-117, a therapeutic complement inhibiting antibody targeting C2Inge Van de Walle, Karen Silence, Kevin Budding, et al.
Physical Review Letters|March 2, 2019
Experimental Evidence for Transverse Wobbling in ^{105}PdJ Timár, Q B Chen, B Kruzsicz, et al.
Parkinsonism & Related Disorders|June 2, 2009
GIGYF2 mutations are not a frequent cause of familial Parkinson's diseaseAlessio Di Fonzo, Edito Fabrizio, Astrid Thomas, et al.
Human Gene Therapy|August 20, 1996
Human gene marker/therapy clinical protocolsS A Rosenberg, R M Blaese, M K Brenner, et al.
Journal of Medical Genetics|November 8, 2005
The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestorS Goldwurm, A Di Fonzo, E J Simons, et al.
Human Gene Therapy|December 28, 1999
Human gene marker/therapy clinical protocolsS A Rosenberg, R M Blaese, M K Brenner, et al.
Human Gene Therapy|December 1, 1996
Human gene marker/therapy clinical protocolsS A Rosenberg, R M Blaese, M K Brenner, et al.
Human Gene Therapy|February 4, 1998
Human gene marker/therapy clinical protocolsS A Rosenberg, R M Blaese, M K Brenner, et al.
European Journal of Human Genetics : EJHG|December 8, 2005
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's diseaseAlessio Di Fonzo, Cristina Tassorelli, Michele De Mari, et al.
Royal Society Open Science|July 25, 2024
Subjective evidence evaluation survey for many-analysts studiesAlexandra Sarafoglou, Suzanne Hoogeveen, Don van den Bergh, et al.
Pageof 82